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Using hepatitis C prevalence to estimate HIV
epidemic potential among people who inject drugs in
the Middle East and North Africa
Ghina R. Mumtaza,b, Helen A. Weissb, Peter Vickermanc,
Natasha Larkeb and Laith J. Abu-Raddada,d,e
Objectives: The objective of this study is to understand the association between HIV
and hepatitis C virus (HCV) among people who inject drugs (PWIDs) in the Middle East
and North Africa (MENA), and to estimate HIV epidemic potential among PWIDs using
HCV prevalence.
Design/methods: Using data from a systematic review of HIV and HCV among PWID
in MENA, we conducted two analyses, stratified by HIV epidemic state: a meta-analysis
of the risk ratio of HCV to HIV prevalence (RRHCV/HIV) using DerSimonian-Laird
random-effects models, and multivariable linear regression predicting log HIV preva-
lence. The HCV-HIV association from both analyses was used to estimate HIV
prevalence at endemic equilibrium. We compared predicted with current HIV preva-
lence to classify HIV epidemic potential at country-level as low, medium or high, using
predefined criteria.
Results: The review identified 88HCV prevalencemeasures among PWID inMENA, of
which 54 had a pairedHIV prevalencemeasure. The pooled RRHCV/HIV were 16, 4 and 3
in low-level, emerging and established HIV epidemics, respectively. There was a
significant linear relationship between HCV and HIV at endemic equilibrium
(P¼0.002). The predicted endemic HIV prevalence ranged between 8% (Tunisia)
and 22% (Pakistan). Of the nine countries with data, five have high and three medium
HIV epidemic potential. Only one country, Pakistan, appears to have reached satur-
ation.
Conclusion: HCV prevalence could be a predictor of future endemic HIV prevalence.
In MENA, we predict that there will be further HIV epidemic growth among PWID. The
proposed methodology can identify PWID populations that should be prioritized for HIV
prevention interventions. Copyright  2015 Wolters Kluwer Health, Inc. All rights reserved.
AIDS 2015, 29:1701–1710
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Introduction
People who inject drugs (PWID) are a key population at
risk for HIV infection in the Middle East and North
Africa (MENA) [1]. A recent systematic review
documented emerging HIV epidemics among PWID
in at least one-third of MENA countries [2]. Most
epidemics are recent and suggest potential for further
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growth [2]. Our research question is to estimate the HIV
epidemic potential among PWID, that is to estimate the
predicted growth in HIV prevalence to the time it reaches
endemic equilibrium, in order to inform policy and
intervention programmes.
Although HIVand, in rare instances [3], hepatitis C virus
(HCV) can be transmitted sexually, sharing of needles/
syringes is their main transmission mode among PWID
[4]. HCV is about 10 times more infectious than HIV
through percutaneous exposure [5–7], partially explain-
ing why HCV is hyperendemic among PWID globally,
but HIV is not [8,9]. As HCV is transmitted more rapidly
than HIV along the same transmission route, it could be
used as a marker of HIV potential spread among PWID.
Ecological studies and mathematical modelling have
found a positive association between HCV and HIV
among PWID globally, with a threshold HCV prevalence
of about 30% to sustain HIV transmission [6,7,10]. The
relationship between the two infections is however
complex, dependent on the setting and risk environment,
and overall remains poorly understood [7].
The use of HCVas a population-level marker of injecting
risk behaviour and, consequently, HIV risk and epidemic
potential is appealing with the constrained resources for
HIV research and programming. In MENA, wherein
surveillance is rather limited and difficult to implement,
using existing data to make inferences about future size of
HIV epidemics is a potentially efficient strategy.
The aims of this study are to understand analytically
the epidemiological links and association between
HCV and HIV infections among PWID, and to
estimate HIV epidemic potential in this population
across MENA countries, using data compiled through
the systematic review of HIV and HCV among PWID
in MENA [2].
Materials and methods
Conceptual framework and hypotheses
We hypothesize that endemic HCV prevalence predicts
HIV prevalence among PWID, as both infections result
from injecting risk behaviour. We further hypothesize
that the relationship between HCVand HIV prevalence
is dependent on the HIV epidemic state among PWID,
whether low-level (HIV has not reached significant
levels), emerging (HIV prevalence has started its initial
growth and is increasing) or established/saturated (the
epidemic has reached its peak and HIV prevalence is
approaching, or already is at, its endemic level) [2]. We
hypothesize that the association between HCVand HIV
in established HIV epidemics can be used to predict
HIVepidemic potential among PWID in other settings,
even where the HIV epidemic is still at low level or
emerging.
Our hypothesis is motivated by theoretical mathematical
modelling work on the joint epidemiology of HCV and
HIV. A stochastic compartmental model was built to
simulate HCV and HIV epidemic trajectories among a
prototype PWID population (V. Akbarzadeh, G.R.
Mumtaz, L.J. Abu-Raddad, in preparation). Figure 1a
depicts a case scenario wherein HIV is introduced into a
PWID population originally naive to HIV and where
HCV is endemic at high prevalence indicating substantial
injecting risk behaviour. When the HIV epidemic is still
at low level, HCV prevalence is not predictive of the level
of HIV prevalence (Fig. 1a). When the HIV epidemic
emerges, HCV prevalence becomes associated with HIV
prevalence; however, the magnitude of this association
varies with time, as HIV prevalence is still increasing
(Fig. 1a). It is only when the HIV epidemic becomes
established, that the association between HCV and HIV
prevalence becomes stable and simply quantified, as both
infections have reached endemicity (Fig. 1a). This pattern
is reflected in the risk ratio of HCV to HIV prevalence
(RRHCV/HIV) (Fig. 1b). As the HIV epidemic emerges,
the RRHCV/HIV decreases until it reaches a plateau, with a
stable RRHCV/HIV, when the HIV epidemic reaches
equilibrium (established HIV epidemic, Fig. 1b). Ende-
mic HCV prevalence can accordingly be used to predict
the future size (at endemic equilibrium) of the HIV
epidemic among PWID. Varying levels of endemic
HCV prevalence entail varying levels of endemic HIV
prevalence.
On the basis of the above analytical framework, we will
stratify our analyses by HIVepidemic state to explore the
differential association between HCV and HIV in the
three epidemic states. Results of the analyses in settings of
established HIV epidemics will be used to predict HIV
epidemic potential among PWID.
Sources of data
This study used data extracted from a recent systematic
review whose main objective was to assess the status of the
HIVepidemic among PWID in 23 MENA countries that
are part of the MENA definition of the Joint United
Nations Programme on HIV/AIDS (UNAIDS), WHO
and World Bank [2]. In brief, the review followed
PRISMA guidelines and included all studies on PWID,
published in PubMed, Embase and regional databases,
and unpublished in the form of country reports, until 16
December 2013 [2].
In the present study, we started with 197 HIV and 93
HCV prevalence measures among PWID (Fig. 2) [2].
After excluding four HIV and five HCV self-reported
prevalence measures, there were 71 paired biological
HCV-HIV data points, that is HCV and HIV prevalence
on the same PWID population. As we are studying the
relationship between the two infections, the analysis was
restricted to settings wherein HIV has already been
introduced, and thus, 16 HCV-HIV data points with zero
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HIV prevalence were excluded. One outlier (89% HIV
prevalence in Libya [11]) was further excluded, leaving 54
paired HCV-HIV prevalence measures in the statistical
analysis (Fig. 2).
Classification by HIV epidemic state
Country-specific criteria were devised to classify the data
into one of three HIV epidemic states: low-level,
emerging or established [2]. This classification was a
main aim of the MENA PWID systematic review,
wherein a comprehensive analysis of available HIV
biological data was performed using rigorous method-
ology to characterize HIVepidemic state at country-level
[2]. HCV biological data were not part of the criteria to
characterize HIVepidemic states. Details of the methods,
classification criteria and findings that led to these
epidemic states can be found in the corresponding
publication [2]. The epidemic states for countries in the
present study are summarized in Table S1. This baseline
classification was adjusted in specific cases to accommo-
date for geographic heterogeneity in HIV epidemic
dynamics within a single country [2]. For example, in
Iran, all data points after 2006 were classified as
‘established’, except for one province, Isfahan, where
HIV prevalence among PWID has been consistently
negligible [2].
Data analysis
Analyses were performed in STATA/SE 13.0 (Stata
Corp., College Station, Texas, USA). Two types of
analyses were conducted to understand the association
between the two infections: a meta-analysis of the
HIV epidemic potential among people who inject drugs Mumtaz et al. 1703
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Fig. 1. Mathematical modelling simulation of an HIV epidemic expansion among a prototype PWID population. (a) A case
scenario for an HIV epidemic expansion in a PWID population wherein HCV is endemic at a prevalence level of about 75%
indicating high injecting risk behaviour. HIV is introduced in 1990, starts emerging with increasing prevalence about two decades
later in the late 1990s, and saturates near the year 2020 at a prevalence of about 20%. The corresponding three HIV epidemic
states – low level, emerging and established – are shown on the graph. (b) The risk ratio of HCV to HIV prevalence (RRHCV/HIV)
among this PWID population.
RRHCV/HIV and linear regression to quantify the extent
to which any change in HIV prevalence is related to
change in HCV prevalence. Results of these analyses were
used to predict future HIV prevalence at endemic
equilibrium among PWID at country-level.
Meta-analysis
Three meta-analyses of the RRHCV/HIV in each of the
three HIVepidemic states were applied. The RRHCV/HIV
is an ‘ecological’ risk ratio defined as the ratio of the
prevalence (‘risk’) of HCV to that of HIV in the same
population. The objective of using this measure was to
quantify the association between the two infections at the
population level.
The 54 RRHCV/HIV were pooled using DerSimonian–
Laird random-effects models with inverse variance
weighting using the metan command [12]. The I2 statistic
was calculated as a measure of heterogeneity in effect size,
which is the proportion of overall between-study
variation in RRHCV/HIV that is due to differences
between studies in effect size and not chance [12].
Linear regression
Three multivariable linear regression models, one in each
HIV epidemic state, were fitted to the data. Log HIV
prevalence was the dependent variable. Explanatory
variables included HCV – our main predictor of interest
– country and study characteristics including sampling
technique (probability versus nonprobability-based),
sample size (<100 or 100) and study site (community,
facility-based or prison). The regression analyses used
robust standard errors to adjust for heteroscedasticity.
Each data point was weighed by its sample size. As a first
step, all explanatory variables were included in the model
and only variables significant at P value less than 0.1 (in
addition to HCV) were kept in the final model.
HIV epidemic potential prediction
The final regression model predicting HIV prevalence in
settings of established HIVepidemics was used to estimate
the prevalence and 95% confidence intervals of HIV at
endemic equilibrium among PWID, using the margins
command. On the basis of predictions of the fitted model,
margins calculate HIV prevalence for specific values of
covariates in the model. The predictions were made using
the mean HCV prevalence among PWID per country
using all available biological HCV prevalence measures
(including where HIV is zero) [11,13–78]. The
prevalence of HIV at endemic equilibrium was also
estimated using results of the meta-analysis by dividing
the mean HCV prevalence by the pooled RRHCV/HIV.
Results of the two methods of prediction were compared.
We devised criteria to classify HIV epidemic potential.
They depend on comparing the predicted HIV prevalence
with the most recent representative HIV prevalence as
extracted from surveillance studies [2]. HIV epidemic
potential was classified as high, moderate or low. High
epidemic potential was considered if the estimated HIV
prevalence at endemic equilibrium was at least 10 absolute
percentage points higher than current HIV prevalence and
at least twice as high as current HIV prevalence (estimated/
current HIV prevalence>2). Low epidemic potential was
considered if the estimated HIV prevalence at endemic
equilibrium was less than five absolute percentage points
higher than current HIV prevalence and less than 20%
higher than current HIV prevalence (estimated/current
HIV prevalence <1.2). Moderate epidemic potential was
considered in remaining scenarios.
Results
The 54 paired HCV-HIV prevalence measures among
PWID were from five countries: Iran (n¼ 31), Afghani-
stan (n¼ 11), Pakistan (n¼ 8), Morocco (n¼ 2) and
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197 HIV prevalence 
measures
93 HCV prevalence 
measures
4 self-reported HIV prevalence 
measures excluded
5 self-reported HCV prevalence 
measures excluded
193 biological HIV 
prevalence measures
88 biological HCV 
prevalence measures
71 paired biological HCV-HIV 
prevalence measures
16 paired data points with zero 
HIV prevalence excluded
1 outlier excluded 
(HIV prevalence = 89%)
54 paired biological HCV-HIV 
prevalence measures included 
in the statistical analyses
Fig. 2. Sample selection process.
Tunisia (n¼ 2). There were 20 paired HCV-HIV
measures in low-level, 22 in emerging, and 12 in
established HIV epidemic settings. Iran was the only
country in the established epidemic strata. The data are
summarized in Table S2.
The meta-analyses showed that the RRHCV/HIV is
highest in low-level HIV epidemics at 16.3 [95%
confidence interval (95% CI) 11.5–23.1], followed by
that in emerging HIVepidemics at 3.8 (95% CI 3.1–4.7),
while the lowest RRHCV/HIV was observed in established
HIV epidemics at 2.8 (95% CI 2.1–3.6) (Table 1). The
corresponding forest plots are in Figures S1–S3. These
results suggest that HIV prevalence at endemic equi-
librium is about one-third of the endemic HCV
prevalence, assuming no major confounding effect by
other predictors. There was evidence of heterogeneity
between studies in the three epidemic states with an I2 of
80–87% (P< 0.001), indicating that the variation in
RRHCV/HIV between studies is due to differences in
effect size, and not chance.
Table 2 summarizes the final multivariable regression
models predicting log HIV prevalence. HCV prevalence
was not associated with HIV in low-level HIVepidemics
(ß¼1.3, 95% CI3.4 to 0.9). In these settings, country
and study site were the significant predictors of HIV.
HCV was a significant predictor of HIV prevalence in
sites wherein the HIV epidemic is emerging or
established. In emerging epidemics, HCV was signifi-
cantly associated with the highest increase in log HIV
prevalence compared with the other epidemic states
(ß¼ 5.4, 95% CI 2.7–8.2). Country and study site were
also significant predictors of HIV in emerging epidemic
states. In established epidemics, HCV prevalence was the
only predictorof HIV (ß¼ 1.7, 95% CI 0.8–2.7) (Table 2).
Table 3 displays the predicted HIV prevalence at endemic
equilibrium among PWID in MENA using results of
both regression analysis and meta-analysis. The two
methods predicted similar endemic HIV prevalence, with
a median difference of 10% between the two methods.
The median estimated HIV prevalence across countries
was 17% [interquartile range (IQR): 13–20%] and 19%
(IQR: 13–22%) as predicted by the regression and meta-
analysis models, respectively. The highest estimated
endemic HIV prevalence was 20–22% in Egypt,
Morocco, Pakistan, Saudi Arabia and Syria. The lowest
was 8% in Tunisia (Table 3).
HIV epidemic potential was found to be high among
PWID in Egypt, Lebanon, Palestine, Saudi Arabia and
Syria, and moderate in Afghanistan, Morocco and
Tunisia. Apart from Iran that was used to derive the
predictive relationship, Pakistan was the only country
with low epidemic potential and where the HIVepidemic
among PWID is predicted to have reached or is close to
saturation (Table 3).
Discussion
This study illustrates our hypothesis that HCV prevalence
can be used to predict HIV epidemic potential among
PWID. With HCV being hyperendemic among PWID
globally, its prevalence is indicative of the level of injecting
risk behaviour and therefore could possibly predict future
HIV prevalence. Our analyses in MENA suggest that
HIV prevalence will reach, at endemic equilibrium,
about one-third of HCV prevalence in a given PWID
population wherein HIV is introduced.
The association between HCVand HIVamong PWID is
complex and varied depending on HIVepidemic state, as
postulated in our hypothesis and motivated by the
modelling simulations. When the HIV epidemic was at
low level, HCV was not predictive of HIV prevalence.
HIV may have been recently introduced, or may have
been spreading for some time but slowly and inefficiently
due to stochastic effects. In these settings, HIV prevalence
is not a reflection of the level of injecting risk behaviour.
In an emerging HIV epidemic, the intensity of HIV
prevalence growth depends on the level of injecting risk
behaviour, and this is confirmed by the observed
association between HCVand HIV prevalence. However,
there are also other predictors of epidemic expansion
intensity including time since epidemic emergence, and
other factors such as setting of injection and country, both
of which were significant predictive proxies for the risk
environment (Table 2). In established HIVepidemics, and
confirming our hypothesis (Fig. 2), HCV was the only
significant predictor of HIV prevalence. This highlights
how HCV is a proxy of injecting risk behaviour in PWID
HIV epidemic potential among people who inject drugs Mumtaz et al. 1705
Table 1. Pooled risk ratio of hepatitis C virus to HIV prevalence (RRHCV/HIV) among people who inject drug in Middle East and North Africa.
Epidemic state No datasets
Total un-weighted Total un-weighted Studies RRHCV/HIV
Pooled RRHCV/HIV
HCV prevalence HIV prevalence Median (IQR) % (95% CI) I2 P
Low level 20 3264/7699 (42.4%) 217/7730 (2.8%) 13.8 (9.6–56.9) 16.3 (11.5–23.1) 80.2% 0.000
Emerging 22 2200/3749 (58.7%) 554/3698 (15.0%) 4.4 (3.1–5.6) 3.8 (3.1–4.7) 79.5% 0.000
Established 12 1635/3498 (51.1%) 605/3508 (23.2%) 3.3 (2.1–4.2) 2.8 (2.1–3.6) 87.2% 0.000
CI, confidence interval; HCV, hepatitis C virus; IQR, interquartile range.
and can be used to generate inferences on the size of HIV
epidemics, regardless of current HIV epidemic state.
HCV prevalence ‘summarizes’ collectively the risk
environment and acts as a ‘temperature scale’ of the
level of risk behaviour and HIV epidemic potential in a
PWID population.
We estimated HIV epidemic potential in nine countries
where HCV prevalence data were available. Both the
regression analysis and meta-analysis produced similar
results, not a surprising outcome, as HCV was the only
significant predictor of HIV in the regression analysis of
established HIV epidemics. In most countries, we found
room for further HIV growth, with five of these having
high and three moderate HIV epidemic potential,
highlighting the emerging and growing nature of the
HIV epidemic among PWID in MENA, as suggested
recently [1,2]. Although HIV prevalence in Pakistan
showed an increasing trend from 10.8% in 2005 to 25.2%
in 2011 [79–82], our predictions suggest that the HIV
epidemic could be reaching saturation with limited
potential for further growth. Still, HIV incidence remains
considerable in such settings of high HIV prevalence, and
the limited epidemic potential should not be interpreted
as low priority for prevention interventions.
Our findings have important policy implications, as they
provide a simple tool to identify PWID populations at a
high risk of future HIV epidemic expansion. In half of
MENA countries with considerable epidemic potential,
the HIVepidemic is still at low level, and therefore, there
is significant benefit in preventing the infection from
taking root in this population. In countries where
epidemic status is unknown, using HCV prevalence data
could help identify hidden HIV epidemics before they
grow substantially. One example is Saudi Arabia where
the high HCV prevalence suggests the potential for
substantial, though undetected, HIV transmission.
Recent case notification data also hint at this conclusion
[1]. Although the top priority for public health
programmes should be settings already at known high
HIV incidence, such country-specific predictions high-
light the need to also implement intervention packages
and conduct surveillance studies in settings with high
HIV epidemic potential and where there could be
complacency in view of the current low HIV prevalence.
There were several limitations in our study. The analysis
used a relatively simple approach to a probably complex
association. We assumed a linear association between
HCVand HIV, which fitted well our data. However, the
effect size can be affected by heterogeneity in risk and
nonlinearity in this association, as suggested by the
observed high I2 values, earlier modelling work [7,10]
and an ecological analysis [6]. The latter also suggests a
threshold effect where HIV prevalence would remain
negligible in countries with low HCV prevalence [6],
such as Tunisia. The HCV-HIV association can also be
affected by interventions, if they affect each infection
differentially, such as antiretroviral therapy (ART) that
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Table 2. Multivariable linear regression modelsa predicting log of HIV among people who inject drug in Middle East and North Africa, stratified
by HIV epidemic state among people who inject drug.
HIV epidemic state Variables b 95% CI P R2
Low level (n¼16) HCV prevalenceb 1.3 3.4 to 0.9 0.216 0.754
Country 0.000
Afghanistan ref
Iran 0.3 1.6 to 1.0
Morocco 1.8 3 to 0.6
Pakistan 0.6 2.4 to 1.1
Tunisia 0.3 1.0 to 1.6
Study site 0.025
Community ref
Prison 1.3 0.3 to 3.0
Facility-based 0.1 1.7 to 1.5
Mixed 0.4 1.3 to 2.1
Emerging (n¼21) HCV prevalenceb 5.4 2.7–8.2 0.001 0.724
Country 0.001
Afghanistan ref
Iran 2.2 3.1 to 1.4
Morocco 0.6 1.1 to 0.2
Pakistan 1.3 2.2 to 0.3
Study site 0.000
Community ref
Prison 1.0 0.1–2.0
Facility-based 2.8 1.3–4.2
Mixed 2.8 2.0–3.7
Established (n¼12) HCV prevalenceb 1.7 0.8–2.7 0.002 0.340
CI, confidence interval.
aWeighting for sample size and using robust methods to adjust for heteroscedasticity. The displayed final models include only statistically
significant covariates.
bProportion.
affects survival with HIV and infection transmission. In
MENA, ART coverage is low across countries, with a
median of 16% (IQR: 6–17%) [83]. If ART coverage
increases substantially in the coming years, our current
predictions may underestimate endemic HIV prevalence
with the longer survival effect. ART can affect the
quantitative HCV-HIV association, but not its existence
nor the principle behind it. When applied to settings with
substantial ART coverage, a more generic association
could be derived by including ART coverage as one
additional covariate in the regression models.
We assumed that HCV and HIV among PWID are
transmitted through sharing of needles/syringes and that
there is limited sexual transmission of these infections in
this population. We also assumed a negligible effect of
background HCV prevalence due to iatrogenic trans-
mission, as HCV prevalence in the population at large is
generally much smaller than HCV prevalence among
PWID [2,84,85]. We further assumed that HCV is at
endemic equilibrium. All of these assumptions are only
approximately valid.
The small sample size of paired HCV-HIV measures
limited the range of mathematical complexity that could
be explored and number of potential confounders to
control for and prevented us from conducting meta-
regressions to account for heterogeneity in effect size. Iran
was also the only country providing data in the established
HIV epidemic state, but this could introduce bias if the
data from other countries are not representative of the
same generic HCV-HIV epidemiological association.
The predictions of HIV epidemic potential also depend
on the quality of HCV prevalence data. For some
countries, there were few measures and these may not be
representative of the PWID population at large. Our
predictions were also made at the national level, but there
could be geographic heterogeneity in risk environment,
leading to geographically clustered HCV prevalence and
predicted HIV epidemic size. For example in Pakistan,
HCV prevalence of over 90% was observed in Karachi
and Lahore [2], while the mean prevalence at the
country-level was only 61%. Finally, our methodology
provides only the scale and not the timeframe of predicted
epidemic growth. It is expected, however, based on
generic mathematical modelling results [11,86], that the
pace of an epidemic should correlate with its HIV
epidemic potential, as estimated here.
Despite these limitations, our study provides important
insights into a poorly understood and barely investigated
association [6,7]. Using a mechanistic and analytical
methodology, our study confirms that the HCV-HIV
association is robust and characterized differentially by
HIVepidemic state. The association can also be described,
at least grossly, using a simple methodology that can be
easily and widely applied to assess HIVepidemic potential.
Even if some of the input data used to generate the
HIV epidemic potential among people who inject drugs Mumtaz et al. 1707
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predictions may prove unrepresentative with further
empirical data, the value of this work remains in
delineating a powerful concept of using data on one
infection, HCV, to estimate the scale of epidemics of
another infection, HIV. This concept exploits the
epidemiological links that underpin the dynamics of
two infections sharing the same mode of transmission and
propagating on the same network structure. With further
data over the coming years, and use of global data on
PWID beyond MENA, the value of this approach can be
enhanced for a wider applicability across countries and
contexts, including fine-grained predictions at small
geographic scales. Moreover, if combined with appro-
priate dynamic mathematical modelling, our results could
be used to generate predictions for the time evolution
of epidemics.
In conclusion, we described a concept that has a
pragmatic and useful application, to predict future HIV
epidemics and their scales using HCV prevalence. The
proof of concept was manifested by modelling the HCV-
HIV association in few countries, and then generating
predictions for more countries with limited HIV data. In
addition to informing our theoretical understanding of
the overlapping epidemiology of these two infections, this
approach optimizes the use of available data and informs
resources allocation and planning of interventions and
research studies. Findings from this proposed method-
ology can complement those of other methods of
measurement and estimation such as prospective inci-
dence studies, and indirect estimations of HIV incidence
using the innovative HIV incidence assays and math-
ematical models [87,88]. Triangulation of complimentary
approaches will allow the corroboration of findings across
different methods, the adjustment of potential limitations
in each one of them and is essential for the formulation of
an optimal HIV response.
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